Retatrutide vs Tirzepatide: The Reta Hype, Tested (2026)
TL;DR: Retatrutide is a triple-receptor agonist (GIP, GLP-1, glucagon) Lilly is moving through Phase 3 in 2026 — Phase 2 reported about 24% body-weight loss at 48 weeks, the most of any GLP-1-class drug to date. Tirzepatide (Mounjaro/Zepbound) is FDA-approved and produces about 22% at 72 weeks. Reta isn't available outside trials yet. Bigger numbers come faster — but the behavioral question of what comes after is the same.
Key Takeaways
- Retatrutide produced ~24% mean weight loss in Phase 2 at 48 weeks. Tirzepatide produced ~22% at 72 weeks in SURMOUNT-1. Reta gets there faster.
- Retatrutide hits three receptors — GIP, GLP-1, and glucagon. That third lever (glucagon) is what differentiates it from tirzepatide's GIP/GLP-1 dual mechanism and from semaglutide's GLP-1-only mechanism.
- Phase 3 TRIUMPH readouts are expected mid-to-late 2026. Until then, retatrutide is investigational — not FDA-approved, not commercially available. Anyone using it now is using research-grade product.
- Side-effect profile in Phase 2 looked GLP-1-typical — nausea, GI distress, transient ALT/AST elevations. Long-term safety is still pending Phase 3.
- Faster results don't guarantee durable results. The behavioral and identity work that makes weight loss stick when medication tapers is the same on reta as on any GLP-1.
What retatrutide actually is
Retatrutide is Eli Lilly's investigational once-weekly injectable peptide. It binds three different receptors in the body:
- GLP-1 (glucagon-like peptide-1) — the appetite-suppression and insulin-sensitivity lever you know from Ozempic, Wegovy, and the GLP-1 component of Mounjaro/Zepbound.
- GIP (glucose-dependent insulinotropic polypeptide) — the second metabolic lever in Mounjaro/Zepbound (tirzepatide).
- Glucagon — the third receptor, novel in this class. Glucagon agonism is associated with increased basal energy expenditure (you burn more calories at rest) and accelerated lipolysis (your body releases fat from storage more readily).
That third receptor is the difference. Semaglutide is single-agonist. Tirzepatide is dual. Retatrutide is triple. Each additional lever pulls a different mechanism, and Phase 2 data suggests the result is faster, larger weight loss.
Phase 2 + Phase 3 data so far
Phase 2 (TRIUMPH-2, 48 weeks):
- 12 mg dose: ~24.2% mean body-weight loss
- 8 mg dose: ~22.8%
- 4 mg dose: ~17.5%
- Placebo: ~2.1%
That 24% number is what generated the social-media wave. To put it in context: every previous GLP-1 class was celebrated for hitting 15% (semaglutide) and then 22% (tirzepatide). Retatrutide hits 24% — and the curve hadn't plateaued at 48 weeks, suggesting the 72-week number could go higher.
Phase 3 (TRIUMPH-1, TRIUMPH-3, TRIUMPH-4): These trials enrolled through 2024–2025 and primary readouts are expected mid-to-late 2026. The FDA decision likely lands in 2027. Investor disclosures from Lilly suggest TRIUMPH-1 (obesity) is on track, but real Phase 3 numbers remain embargoed at the time of writing.
How it compares to tirzepatide
| Retatrutide | Tirzepatide (Mounjaro / Zepbound) | |
|---|---|---|
| Mechanism | Triple agonist (GIP + GLP-1 + glucagon) | Dual agonist (GIP + GLP-1) |
| Best Phase 2/3 weight loss | ~24% at 48 weeks (Phase 2) | ~22% at 72 weeks (Phase 3) |
| FDA status | Phase 3, expected 2027 | Approved 2022 (T2D), 2023 (obesity) |
| Form | Once-weekly injection | Once-weekly injection |
| Available now | Trials only | Yes, prescription |
| Expected price (post-launch) | Likely premium tier | $1,069/mo list, $25/mo with savings card |
| Cardiovascular outcomes data | Not yet available | SURPASS-CVOT pending |
| Liver safety signals | Transient ALT/AST elevation in Phase 2 | Generally well tolerated |
The faster-and-larger answer is real. But the "available now" line matters more than the percent-loss line for almost everyone reading this. Tirzepatide is something you can fill at a pharmacy this week. Retatrutide is something you might be able to consider in 2027 or 2028.
Side-effect profile
Phase 2 retatrutide side effects looked GLP-1-typical:
- Nausea, vomiting, diarrhea — most common, dose-dependent, mostly transient (peaks during titration, fades by month 3 for most users)
- Constipation — meaningful subset
- Transient elevations in ALT/AST (liver enzymes) — flagged in Phase 2; will be a closely-watched data point in Phase 3
- Heart-rate uptick — small, mechanism-related to glucagon receptor
The "rage" and "binge eating cured" Reddit threads about reta point to two real patterns: people using research-grade compounded reta sometimes experience faster-than-comfortable appetite changes; and the rapid weight loss can surface emotional and identity stress that a slower curve doesn't. Both apply to tirzepatide too — they're just compressed on reta.
For a deeper look at how retatrutide is being discussed in real user communities, our Penn AI Reddit study analysis covers the methodology used to surface these signals.
Why faster results don't equal durable results
This is where retatrutide stops being a pharmacology story and starts being a behavioral one.
Every GLP-1 trial that has reported follow-up after medication taper or discontinuation shows the same pattern: weight regain. The original SURMOUNT-4 trial showed that withdrawal of tirzepatide led to ~14% weight regain within 12 months. The STEP-4 trial on semaglutide showed similar retention dynamics. The phenomenon doesn't disappear because the medication produces 24% loss instead of 22% — if anything, larger losses can mean larger regains because the body's homeostatic pull is proportional.
What changes the durability isn't a third receptor. It's what gets built underneath the medication: protein-anchored eating, resistance training that defends muscle, sleep that supports metabolic recovery, an identity layer that doesn't depend on the scale to feel okay. The medication is the lever. The handle is what you do with the year you got back.
If you're watching retatrutide and feeling impatient, the productive question isn't when does this drug land. It's what habits would I want to have already built by the time I have access to it.
For a structured way to assess where your habits actually are right now, our habit-readiness assessment is a 10-minute self-reflection that maps strengths and gaps without grading you. And for the broader argument about durability, our piece on building habits that outlast your GLP-1 prescription covers the underlying playbook. The follow-up question — what actually happens after people stop — is in weight regain after stopping GLP-1: research.
When and if retatrutide will be available
Best estimate as of May 2026: TRIUMPH-1 primary endpoint readout in second half of 2026, FDA filing late 2026, decision in 2027. Commercial launch 2027 if approved.
Pricing is unknown but Lilly has telegraphed a premium tier for retatrutide given the efficacy profile. Whether savings programs and Lilly Direct extend to it on day one is also unknown. The compounded peptide market will move quickly to fill the gap — that comes with the same regulatory and quality risks that the FDA 503B compounded GLP-1 ban proposal is now addressing for sema and tirz.
Frequently asked questions
Is retatrutide available right now? Not as an FDA-approved consumer medication. Retatrutide is in Phase 3 trials. Anyone using "reta" outside a clinical trial is using research-grade compounded peptide, which is not regulated for human consumption and carries quality, dosing, and legal risk. The FDA has not approved retatrutide for any indication as of May 2026.
How does retatrutide compare to tirzepatide? Same form (weekly injection), different mechanism. Tirzepatide is GIP + GLP-1 dual agonist. Retatrutide adds a third receptor — glucagon — which contributes basal-energy-expenditure increase. Phase 2 retatrutide showed ~24% weight loss at 48 weeks vs ~22% for tirzepatide at 72 weeks. Real comparison data won't exist until retatrutide finishes Phase 3.
What are the side effects of retatrutide? Phase 2 reported GLP-1-typical effects: nausea, vomiting, diarrhea, constipation, dose-dependent and titration-related. The retatrutide-specific watch points are transient liver-enzyme elevations and small heart-rate increases related to glucagon receptor activity. Long-term safety is pending Phase 3 readouts.
Is retatrutide safer than tirzepatide? Unknown. Phase 2 data is short and small. Phase 3 will determine the long-term safety profile. Tirzepatide has 4+ years of post-marketing safety data; retatrutide has none.
When will retatrutide be approved by the FDA? Best public estimate: 2027 if Phase 3 readouts (mid-to-late 2026) support it. Lilly has not given a firm filing date.
This is informational only and not medical advice. Retatrutide is not FDA-approved. Talk to your prescriber before changing any GLP-1 regimen. Phase 2 efficacy and safety figures are from peer-reviewed publications and Lilly investor disclosures current as of May 2026; Phase 3 results are pending.
Sources:
- New England Journal of Medicine. "Retatrutide for the treatment of obesity — Phase 2 trial." 2023.
- Eli Lilly and Company. TRIUMPH program investor disclosures. 2024–2026.
- New England Journal of Medicine. SURMOUNT-1 trial (tirzepatide for chronic weight management). 2022, follow-up 2025.
- New England Journal of Medicine. SURMOUNT-4 trial (tirzepatide withdrawal and weight regain). 2024.
Ready to start your GLP-1 journey?
Gila helps you build lasting habits, understand your body, and stay on track. Join the pilot for free.
Join the Pilot
